Brattea, a Leading Renal Denervation Company in China, Completes over $US20 Million Series B+ Financing, led by Kuanping Capital 06-Apr-2021 Intellasia | PR Newswire Asia | 7:00 PM

SHANGHAI , April 6, 2021 /PRNewswire/ — Brattea, a leading renal denervation (RDN) medical technology company in China , announced today its successful completion of over $US20 million Series B+ financing led by healthcare private equity fund Kuanping Capital.…

This data comes from the ChinaPulse.com media intelligence and smart news insights monitoring platform.